Ivabradine reduces heart rate while preserving metabolic fluxes and energy status of healthy normoxic working hearts

Lauzier B, Vaillant F, Gelinas R, Bouchard B, Brownsey R, Thorin E, Tardif JC, Des Rosiers C. Ivabradine reduces heart rate while preserving metabolic fluxes and energy status of healthy normoxic working hearts. Am J Physiol Heart Circ Physiol 300: H845-H852, 2011. First published January 21, 2011; doi:10.1152/ajpheart.01034.2010.-Heart rate reduction (HRR) is an important target in the management of patients with chronic stable angina. Most available drugs for HRR, such as beta-blockers, have adverse effects, including on cardiac energy substrate metabolism, a well-recognized determinant of cardiac homeostasis. This study aimed at 1) testing whether HRR by ivabradine (IVA) alters substrate metabolism in the healthy normoxic working heart and 2) comparing the effect of IVA with that of the beta-blocker metoprolol (METO). This was assessed using our well-established model of ex vivo mouse heart perfusion in the working mode, which enables concomitant evaluation of myocardial contractility and metabolic fluxes using C-13-labeled substrates. Hearts were perfused in the absence (controls; n = 10) or presence of IVA (n = 10, 3 mu M) with or without atrial pacing to abolish HRR in the IVA group. IVA significantly reduced HR (35 +/- 5%) and increased stroke volume (39 +/- 9%) while maintaining similar cardiac output, contractility, power, and efficiency. Effects of IVA on HR and stroke volume were reversed by atrial pacing. At the metabolic level, IVA did not impact on substrate selection to citrate formation, rates of glycolysis, or tissue levels of high-energy phosphates. In contrast, METO, at concentrations up to 40 mu M, decreased markedly cardiac function (flow: 25 +/- 6%; stroke volume: 30 +/- 10%; contractility: 31 +/- 9%) as well as glycolysis (2.9-fold) but marginally affected HR. Collectively, these results demonstrate that IVA selectively reduces HR while preserving energy substrate metabolism of normoxic healthy working mouse hearts perfused ex vivo, a model that mimics to some extent the denervated transplanted heart. Our results provide the impetus for testing selective HRR by IVA on cardiac substrate metabolism in pathological models.